92 related articles for article (PubMed ID: 21722318)
1. Dz13: c-Jun downregulation and tumour cell death.
Elahy M; Dass CR
Chem Biol Drug Des; 2011 Dec; 78(6):909-12. PubMed ID: 21722318
[TBL] [Abstract][Full Text] [Related]
2. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents.
Zhang G; Dass CR; Sumithran E; Di Girolamo N; Sun LQ; Khachigian LM
J Natl Cancer Inst; 2004 May; 96(9):683-96. PubMed ID: 15126605
[TBL] [Abstract][Full Text] [Related]
3. Dz13 induces a cytotoxic stress response with upregulation of E2F1 in tumor cells metastasizing to or from bone.
Dass CR; Tan ML; Galloway SJ; Choong PF
Oligonucleotides; 2010 Apr; 20(2):79-91. PubMed ID: 20406096
[TBL] [Abstract][Full Text] [Related]
4. DNAzyme targeting c-jun suppresses skin cancer growth.
Cai H; Santiago FS; Prado-Lourenco L; Wang B; Patrikakis M; Davenport MP; Maghzal GJ; Stocker R; Parish CR; Chong BH; Lieschke GJ; Wong TW; Chesterman CN; Francis DJ; Moloney FJ; Barnetson RS; Halliday GM; Khachigian LM
Sci Transl Med; 2012 Jun; 4(139):139ra82. PubMed ID: 22723462
[TBL] [Abstract][Full Text] [Related]
5. The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity.
Rivory L; Tucker C; King A; Lai A; Goodchild A; Witherington C; Gozar MM; Birkett DJ
Oligonucleotides; 2006; 16(4):297-312. PubMed ID: 17155906
[TBL] [Abstract][Full Text] [Related]
6. Dz13, a DNAzyme targeting c-jun, induces off-target cytotoxicity in endothelial cells with features of nonapoptotic programmed cell death.
Gozar MM; Goodchild A; Passioura T; King A; Lai A; Witherington C; Rivory L
Oligonucleotides; 2008 Sep; 18(3):257-68. PubMed ID: 18699742
[TBL] [Abstract][Full Text] [Related]
7. Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity.
Dass CR; Friedhuber AM; Khachigian LM; Dunstan DE; Choong PF
J Microencapsul; 2008 Sep; 25(6):421-5. PubMed ID: 18465314
[TBL] [Abstract][Full Text] [Related]
8. Tetrahedral DNA Nanostructure-Delivered DNAzyme for Gene Silencing to Suppress Cell Growth.
Meng L; Ma W; Lin S; Shi S; Li Y; Lin Y
ACS Appl Mater Interfaces; 2019 Feb; 11(7):6850-6857. PubMed ID: 30698411
[TBL] [Abstract][Full Text] [Related]
9. Dz13, a c-jun DNAzyme, is a potent inducer of caspase-2 activation.
Dass CR; Galloway SJ; Choong PF
Oligonucleotides; 2010 Jun; 20(3):137-46. PubMed ID: 20180631
[TBL] [Abstract][Full Text] [Related]
10. Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression.
Zhang G; Luo X; Sumithran E; Pua VS; Barnetson RS; Halliday GM; Khachigian LM
Oncogene; 2006 Nov; 25(55):7260-6. PubMed ID: 16785994
[TBL] [Abstract][Full Text] [Related]
11. c-Jun Is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model.
Dass CR; Khachigian LM; Choong PF
Mol Cancer Res; 2008 Aug; 6(8):1289-92. PubMed ID: 18708361
[TBL] [Abstract][Full Text] [Related]
12. Melanoma protective antitumor immunity activated by catalytic DNA.
Cai H; Cho EA; Li Y; Sockler J; Parish CR; Chong BH; Edwards J; Dodds TJ; Ferguson PM; Wilmott JS; Scolyer RA; Halliday GM; Khachigian LM
Oncogene; 2018 Sep; 37(37):5115-5126. PubMed ID: 29844573
[TBL] [Abstract][Full Text] [Related]
13. Sequence-related off-target effect of Dz13 against human tumor cells and safety in adult and fetal mice following systemic administration.
Dass CR; Choong PF
Oligonucleotides; 2010 Apr; 20(2):51-60. PubMed ID: 20148692
[TBL] [Abstract][Full Text] [Related]
14. DNAzymes: cutting a path to a new class of therapeutics.
Khachigian LM
Curr Opin Mol Ther; 2002 Apr; 4(2):119-21. PubMed ID: 12044032
[TBL] [Abstract][Full Text] [Related]
15. DNAzymes Dz13 target the c-jun possess antiviral activity against influenza A viruses.
Zhang Z; Zhang S; Wang S
Microb Pathog; 2017 Feb; 103():155-161. PubMed ID: 28039102
[TBL] [Abstract][Full Text] [Related]
16. Destroying c-jun Messenger: new insights into biological mechanisms of DNAzyme function.
Khachigian LM; Cai H; Moloney FJ; Parish CR; Chong BH; Stocker R; Barnetson RS; Halliday GM
Oncotarget; 2012 Jun; 3(6):594-5. PubMed ID: 22805148
[TBL] [Abstract][Full Text] [Related]
17. c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun.
Khachigian LM; Fahmy RG; Zhang G; Bobryshev YV; Kaniaros A
J Biol Chem; 2002 Jun; 277(25):22985-91. PubMed ID: 11891228
[TBL] [Abstract][Full Text] [Related]
18. c-Jun DNAzymes inhibit myocardial inflammation, ROS generation, infarct size, and improve cardiac function after ischemia-reperfusion injury.
Luo X; Cai H; Ni J; Bhindi R; Lowe HC; Chesterman CN; Khachigian LM
Arterioscler Thromb Vasc Biol; 2009 Nov; 29(11):1836-42. PubMed ID: 19592465
[TBL] [Abstract][Full Text] [Related]
19. C-jun: pharmaceutical target for DNAzyme therapy of multiple pathologies.
Dass CR; Choong PF
Pharmazie; 2008 Jun; 63(6):411-4. PubMed ID: 18604982
[TBL] [Abstract][Full Text] [Related]
20. Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun.
Fahmy RG; Waldman A; Zhang G; Mitchell A; Tedla N; Cai H; Geczy CR; Chesterman CN; Perry M; Khachigian LM
Nat Biotechnol; 2006 Jul; 24(7):856-63. PubMed ID: 16823369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
